Braveheart Bio, Inc. reported results
SEC 8-KRead source ↗
Braveheart Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders10 buying, 0 selling13 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 194% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Latest results
- Earnings per share
- -$2.51 against an average estimate of $2.69: missed by 193.5%
- Share reaction
- +8.1% in the first session after the results on September 8, 2026, against -1.0% for the S&P 500
- Next report
- November 12, 2026
Price chart
- 1 day-2.2%
- 1 week-3.8%
- 1 month-1.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- September 8, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Governance
Braveheart Bio, Inc. amended its charter or bylaws
SEC 8-KRead source ↗ - Insider trade
Murdoch Travis (CEO and President) bought $1.5M of stock
SEC Form 4 - Insider trade
Viehbacher Christopher (Director) bought $1.5M of stock
SEC Form 4 - Insider trade
Forbion Growth Opportunities Fund Iii Cooperatief U.A. (10% owner) bought $64.8M of stock
SEC Form 4 - Insider trade
Orbimed Genesis Gp Llc (Director) bought $34.9M of stock
SEC Form 4 - Insider trade
Chimovits Erez (Director) bought $34.9M of stock
SEC Form 4 - Insider trade
Andreessen Marc L (10% owner) bought $19.8M of stock
SEC Form 4
No model value for Braveheart Bio, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Braveheart Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Braveheart Bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close. Analysts expect revenue of $0 for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.78 | +90% | — | — |
| Next | −$1.62 | +9% | — | 0% |
How the EPS forecast has moved
In the last 30 days, 0 analysts raised Braveheart Bio, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 30 days ago | −$1.47 | −$1.62 |
| 7 days ago | −$1.47 | −$1.62 |
| Now | −$1.78 | −$1.62 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $2.69 | −$2.51 | −193.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- — of tradable shares
- Days to cover
- 8.11 at average volume
- Short interest, 1 month
- +99% to October 15, 2026
- Held by institutions
- 28% of shares
- Held by insiders
- 58.2% of shares
- Employees
- 49 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −10.0%
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Share price after results
- Next day
- 1 up, 0 down typical move ±8.1%
- After a week
- 0 up, 1 down typical move ±0.1%
- After a month
- 0 up, 1 down typical move ±30.5%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| September 8, 2026 | +8.1% | −1.0% | −0.1% | −30.5% |
Fundamentals
Insider trading activity
Full insider history and chart Insider purchases History → $159M 13 trades by 10 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $159M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Lubner David Charles Director | August 7, 2026 | Buy | 55,555 | $18.00 | $999,990 |
| Murdoch Travis CEO and President | August 7, 2026 | Buy | 83,333 | $18.00 | $1.5M |
| Anderson Michele A. Chief Development Officer | August 7, 2026 | Buy | 1,111 | $18.00 | $19,998 |
| Malek David I Director | August 7, 2026 | Buy | 4,166 | $18.00 | $74,988 |
| Viehbacher Christopher Director | August 7, 2026 | Buy | 83,333 | $18.00 | $1.5M |
| Rickey James Paul Chief Financial Officer | August 7, 2026 | Buy | 27,777 | $18.00 | $499,986 |
| Forbion Growth Opportunities Fund Iii Cooperatief U.A. 10% owner | August 7, 2026 | Buy | 1,920,000 | $18.00 | $34.6M |
| Forbion Growth Opportunities Fund Iii Cooperatief U.A. 10% owner | August 7, 2026 | Buy | 1,680,000 | $18.00 | $30.2M |
| Orbimed Genesis Gp Llc Director | August 7, 2026 | Buy | 273,333 | $18.00 | $4.9M |
| Orbimed Genesis Gp Llc Director | August 7, 2026 | Buy | 1,666,667 | $18.00 | $30M |
| Chimovits Erez Director | August 7, 2026 | Buy | 273,333 | $18.00 | $4.9M |
| Chimovits Erez Director | August 7, 2026 | Buy | 1,666,667 | $18.00 | $30M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- September 8, 2026
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-1 S-1
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Braveheart Bio, Inc. in brief
- What does Braveheart Bio, Inc. do?
- Braveheart Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Braveheart Bio, Inc.'s stock ticker?
- Braveheart Bio, Inc. trades under the ticker BRVE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Are insiders buying or selling Braveheart Bio, Inc. stock?
- Over the last 12 months, Braveheart Bio, Inc.'s directors and officers reported 13 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Braveheart Bio, Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Braveheart Bio, Inc. announces its own schedule.
Follow research on Braveheart Bio, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.